Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targeted Locus Amplification (TLA) technology, announced the completion of a successful analytical validation study in lymphoma to show the benefits of TLA for the detection of clinically relevant translocations in tumor biopsies. The results of this study, performed in collaboration with researchers from Hubrecht Institute and lymphoma experts of 5 Dutch pathology labs (UMCU, Amsterdam UMC, UMCG, LUMC, and LabPON), have now been published in Nature Communications.
The FFPE-TLC approach promises to revolutionize lymphoma diagnostics and as the technology fits a standard targeted NGS workflow and allows for detection of all clinically relevant mutations, both small and large, in a single diagnostic test. This is especially relevant for precious needle biopsies with limited material available, opening opportunities to improve diagnoses and patient treatments for many more cancer types.
Prof. Daphne de Jong, hematopathologist at Amsterdam University Medical Centre and one of the collaborators said, “The FFPE-TLC approach can greatly improve lymphoma diagnostics and promises to be the hoped-for alternative for cumbersome FISH analyses.”
“We are very proud of the results of this technological breakthrough. In collaboration with thought leaders at Hubrecht Institute and renowned clinical institutions, we have demonstrated the value of FFPE-TLC technology for cancer diagnostics.” Joris Schuurmans, CEO of Cergentis, stated. “With this recognition in hand we are set out to make the technology available for use in pathology labs to help improve diagnosis of patients suffering from lymphoma and other cancer types.”
Edited by Maryssa Gordon, Senior Editor, Price of Business Digital Network
